Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_2
1
14%
Ph phase_3
3
43%
Ph not_applicable
2
29%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
3(42.9%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Other(1)

Detailed Status

Completed6
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 33 (42.9%)
N/A2 (28.6%)

Trials by Status

completed686%
unknown114%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

NCT04690556
completedphase_3

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03150589
completedphase_1

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

NCT00500344
completednot_applicable

Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD

NCT01269151
completednot_applicable

Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

NCT01638858
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04690556Phase 3

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Completed
NCT03150589Phase 3

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Completed
NCT00500344Phase 1

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

Completed
NCT01269151Not Applicable

Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD

Completed
NCT01638858Not Applicable

Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

Completed
NCT00516464Phase 3

Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Unknown
NCT00344227Phase 2

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7